Diabetes, Vol 38, Issue 3 338-342, Copyright © 1989 by American Diabetes Association

ARTICLES

Glucagonlike peptide I (7-37) actions on endocrine pancreas

GC Weir, S Mojsov, GK Hendrick and JF Habener
Joslin Diabetes Center, Boston, MA 02215.

Glucagonlike peptide I (7-37) [GLP-I-(7-37)], encoded with glucagon and glucagonlike peptide II and intervening peptide II in the rat and human glucagon gene, is processed from proglucagon in both pancreas and intestine and is a potent stimulator of insulin secretion. Unequivocal insulin release from the isolated perfused rat pancreas is elicited by a 10(-11) M concentration of this peptide, and a weak response is found at 10(-12) M. We found that GLP-I-(7-37) is approximately 100 times more potent than glucagon in the stimulation of insulin secretion. Insulin release in response to GLP-I-(7-37) is highly dependent on the ambient glucose concentration; no response is detectable at a glucose concentration of 2.8 mM, and at 6.6 and 16.7 mM, insulin release is augmented by 4.7 and 22.8 ng/ml, respectively. The pattern of insulin secretion stimulated by GLP-I-(7-37) is biphasic, with an initial spike followed by a plateau of sustained release. The effects on insulin release of GLP-I-(7-36) amide, a GLP-I analogue, and GLP-I-(7-37) at concentrations of 10(-11) M were indistinguishable. We also found that GLP-I-(7-37) at 10(-9) M does not influence glucagon secretion and that glucagonlike peptide II and the intervening peptide II, two other peptides encoded by the glucagon gene, have no detectable effects on insulin secretion.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. R. Bloom, F. P. Kuhajda, I. Laher, X. Pi-Sunyer, G. V. Ronnett, T. M.M. Tan, and D. S. Weigle The Obesity Epidemic: Pharmacological Challenges Mol. Interv., April 1, 2008; 8(2): 82 - 98. [Abstract] [Full Text] [PDF]

				G. G. Holz, E. Heart, and C. A. Leech Synchronizing Ca2+ and cAMP oscillations in pancreatic {beta}-cells: a role for glucose metabolism and GLP-1 receptors?Focus on "Regulation of cAMP dynamics by Ca2+ and G protein-coupled receptors in the pancreatic {beta}-cell: a computational approach" Am J Physiol Cell Physiol, January 1, 2008; 294(1): C4 - C6. [Full Text] [PDF]

				J. Ryskjaer, C. F Deacon, R. D Carr, T. Krarup, S. Madsbad, J. Holst, and T. Vilsboll Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake Eur. J. Endocrinol., September 1, 2006; 155(3): 485 - 493. [Abstract] [Full Text] [PDF]

				C. Q. Pan, J. M. Buxton, S. L. Yung, I. Tom, L. Yang, H. Chen, M. MacDougall, A. Bell, T. H. Claus, K. B. Clairmont, et al. Design of a Long Acting Peptide Functioning as Both a Glucagon-like Peptide-1 Receptor Agonist and a Glucagon Receptor Antagonist J. Biol. Chem., May 5, 2006; 281(18): 12506 - 12515. [Abstract] [Full Text] [PDF]

				P. Vazquez, I. Roncero, E. Blazquez, and E. Alvarez The cytoplasmic domain close to the transmembrane region of the glucagon-like peptide-1 receptor contains sequence elements that regulate agonist-dependent internalisation J. Endocrinol., July 1, 2005; 186(1): 221 - 231. [Abstract] [Full Text] [PDF]

				P. Vazquez, I. Roncero, E. Blazquez, and E. Alvarez Substitution of the cysteine 438 residue in the cytoplasmic tail of the glucagon-like peptide-1 receptor alters signal transduction activity J. Endocrinol., April 1, 2005; 185(1): 35 - 44. [Abstract] [Full Text] [PDF]

				H. Harder, L. Nielsen, T. D.T. Thi, and A. Astrup The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes Diabetes Care, August 1, 2004; 27(8): 1915 - 1921. [Abstract] [Full Text] [PDF]

				G. Kwon, K. L. Pappan, C. A. Marshall, J. E. Schaffer, and M. L. McDaniel cAMP Dose-dependently Prevents Palmitate-induced Apoptosis by Both Protein Kinase A- and cAMP-Guanine Nucleotide Exchange Factor-dependent Pathways in {beta}-Cells J. Biol. Chem., March 5, 2004; 279(10): 8938 - 8945. [Abstract] [Full Text] [PDF]

				C. Thorkildsen, S. Neve, B. D. Larsen, E. Meier, and J. S. Petersen Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 490 - 496. [Abstract] [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]

				R. L. Prigeon, S. Quddusi, B. Paty, and D. A. D'Alessio Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E701 - E707. [Abstract] [Full Text] [PDF]

				T. Vilsboll, T. Krarup, J. Sonne, S. Madsbad, A. Volund, A. G. Juul, and J. J. Holst Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2706 - 2713. [Abstract] [Full Text] [PDF]

				Y. Anini and P. L. Brubaker Role of Leptin in the Regulation of Glucagon-Like Peptide-1 Secretion Diabetes, February 1, 2003; 52(2): 252 - 259. [Abstract] [Full Text] [PDF]

				B. Rolin, M. O. Larsen, C. F. Gotfredsen, C. F. Deacon, R. D. Carr, M. Wilken, and L. B. Knudsen The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta -cell mass in diabetic mice Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E745 - E752. [Abstract] [Full Text] [PDF]

				E. J. Abraham, C. A. Leech, J. C. Lin, H. Zulewski, and J. F. Habener Insulinotropic Hormone Glucagon-Like Peptide-1 Differentiation of Human Pancreatic Islet-Derived Progenitor Cells into Insulin-Producing Cells Endocrinology, August 1, 2002; 143(8): 3152 - 3161. [Abstract] [Full Text] [PDF]

				A. Vella, P. Shah, R. Basu, A. Basu, M. Camilleri, W. F. Schwenk, and R. A. Rizza Effect of enteral vs. parenteral glucose delivery on initial splanchnic glucose uptake in nondiabetic humans Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E259 - E266. [Abstract] [Full Text] [PDF]

				K. Moens, V. Berger, J.-M. Ahn, C. Van Schravendijk, V. J. Hruby, D. Pipeleers, and F. Schuit Assessment of the Role of Interstitial Glucagon in the Acute Glucose Secretory Responsiveness of In Situ Pancreatic {beta}-Cells Diabetes, March 1, 2002; 51(3): 669 - 675. [Abstract] [Full Text] [PDF]

				A. Vella, P. Shah, R. Basu, A. Basu, M. Camilleri, F. W. Schwenk, J. J. Holst, and R. A. Rizza Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes Diabetes, March 1, 2001; 50(3): 565 - 572. [Abstract] [Full Text]

				T. Vilsbøll, T. Krarup, C. F. Deacon, S. Madsbad, and J. J. Holst Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients Diabetes, March 1, 2001; 50(3): 609 - 613. [Abstract] [Full Text]

				J. T. Lewis, B. Dayanandan, J. F. Habener, and T. J. Kieffer Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist Endocrinology, October 1, 2000; 141(10): 3710 - 3716. [Abstract] [Full Text] [PDF]

				S. Mojsov Glucagon-like Peptide-1 (GLP-1) and the Control of Glucose Metabolism in Mammals and Teleost Fish Integr. Comp. Biol., April 1, 2000; 40(2): 246 - 258. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				B. Ahren and G. Pacini Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice Am J Physiol Endocrinol Metab, December 1, 1999; 277(6): E996 - E1004. [Abstract] [Full Text] [PDF]

				Y. Rouille, S. Kantengwa, J.-C. Irminger, and P. A. Halban Role of the Prohormone Convertase PC3 in the Processing of Proglucagon to Glucagon-like Peptide 1 J. Biol. Chem., December 26, 1997; 272(52): 32810 - 32816. [Abstract] [Full Text] [PDF]

				C. Montrose-Rafizadeh, H. Yang, B. D. Rodgers, A. Beday, L. A. Pritchette, and J. Eng High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor J. Biol. Chem., August 22, 1997; 272(34): 21201 - 21206. [Abstract] [Full Text] [PDF]

				C. Widmann, W. Dolci, and B. Thorens Heterologous Desensitization of the Glucagon-like Peptide-1 Receptor by Phorbol Esters Requires Phosphorylation of the Cytoplasmic Tail at Four Different Sites J. Biol. Chem., August 16, 1996; 271(33): 19957 - 19963. [Abstract] [Full Text] [PDF]